Bristol-Myers Squibb (BMY): The US Food and Drug Administration (FDA) has granted accelerated approval to repotrectinib (brand name Augtyro) for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NTRK) in adults.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.